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Open acAbstract Background: Cisplatin-based chemotherapy (etoposide 100 mg/m2 days 1–5, meth-
otrexate 300 mg/m2 day 1, cyclophosphamide 600 mg/m2 day 1, actinomycin D 0.6 mg/m2 day
2 and cisplatin 60 mg/m2 day 4, EMACP) was compared to EMA/CO (etoposide 100 mg/m2
days 1–2, methotrexate 300 mg/m2 day 1 and actinomycin D 0.5 mg i.v. bolus day 1 and
0.5 mg/m2 day 2, alternating with cyclophosphamide 600 mg/m2 day 8 and vincristine
1 mg/m2 day 8) for the treatment of high-risk gestational trophoblastic neoplasia (GTN).
Patients and methods: In the Netherlands, 83 patients were treated with EMACP and 103
patients with EMA/CO. Outcome measures were remission rate, median number of courses
to achieve normal human chorionic gonadotrophin (hCG) concentrations, toxicity, recurrent
disease rate and disease speciﬁc survival.
Results: Remission rates were similar (EMACP 91.6%, EMA/CO 85.4%). The median number
of courses of EMA/CO to reach hCG normalisation for single-agent resistant disease and pri-
mary high-risk disease was three and ﬁve courses, respectively, compared to 1.5 (p = 0.001)
and three (p < 0.001) courses of EMACP. Patients treated with EMACP more often developed15
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C. Lybol et al. / European Journal of Cancer 49 (2013) 860–867 861fever, renal toxicity, nausea and diarrhoea compared to patients treated with EMA/CO.
Patients treated with EMA/CO more often had anaemia, neuropathy and hepatotoxicity.
Conclusion: EMACP combination chemotherapy is an effective treatment for high-risk GTN,
with a remission rate comparable to EMA/CO. However, the difference in duration of treat-
ment is only slightly shorter with EMACP. Cisplatin-based chemotherapy in the form of
EMACP in this study was not proven more effective than EMA/CO.
 2012 Elsevier Ltd. Open access under the Elsevier OA license. 1. Introduction
Gestational trophoblastic disease (GTD) comprises a
spectrum of disorders, ranging from the premalignant
complete and partial hydatidiform moles (CHM and
PHM, respectively), to gestational trophoblastic neopla-
sia (GTN) consisting of invasive moles, choriocarci-
noma, placental site trophoblastic tumours (PSTT)
and the rare epithelioid trophoblastic tumour (ETT).
Patients with GTN are classiﬁed as having low-risk or
high-risk disease using the modiﬁed WHO prognostic
scoring system as adapted by FIGO.1 Patients with a
score of 0–6 are deﬁned as having low-risk disease.
These patients are treated with single-agent chemother-
apy, consisting of either methotrexate (MTX) or actino-
mycin D. For high-risk patients (prognostic score of 7 or
more) single-agent chemotherapy is considered insuﬃ-
cient treatment and they are therefore treated with
multi-agent chemotherapy.2
Before the introduction of multi-agent chemotherapy
in the 1970s, only 31% of the high-risk patients would be
cured with single-agent chemotherapy.3 Throughout the
late 1970s, the combination of MTX, actinomycin D
and cyclophosphamide or chlorambucil (MAC) became
the preferred ﬁrst-line chemotherapy, followed by the
combination regimen of cyclophosphamide, hydroxy-
urea, actinomycin D, MTX, vincristine and doxorubicin
(CHAMOCA) in the early 1980s.2,4,5 In 1982, an alter-
native schedule to CHAMOCA was designed by the
Dutch Working Party on Trophoblastic Disease, con-
sisting of etoposide, MTX, actinomycin D, cyclophos-
phamide and cisplatin (EMACP), aiming to design a
schedule that could be repeated frequently with a short
interval between two courses, causing less myelosup-
pression and containing the new agents etoposide and
cisplatin.6,7 Today, the most widely accepted initial
treatment for high-risk trophoblastic tumour is EMA/
CO chemotherapy (etoposide, MTX and actinomycin
D, alternating with cyclophosphamide and vincristine)
introduced in 1979 by Newlands and Bagshawe, show-
ing complete remission rates ranging from 69% to
86%.8–11 However, due to the favourable outcome fol-
lowing treatment, some centres in the Netherlands pre-
ferred to continue application of the EMACP schedule
after the introduction of EMA/CO. The aim of the pres-
ent study was to evaluate the eﬃcacy and safety of cis-
platin-based combination chemotherapy (EMACP) ascompared to the EMA/CO schedule for the treatment
of high risk GTN.
2. Patients and methods
2.1. Patients
In the Netherlands, patients with GTD are registered
at the Dutch Central Registry for Hydatidiform Moles
(DCRHM) residing at the Radboud University
Nijmegen Medical Centre (RUNMC). This voluntary
registry serves as an epidemiological database and pro-
vides a national human chorionic gonadotrophin
(hCG) assay service to gynaecologists. Patients with
GTD, and even GTN are treated in various referral
hospitals. The Dutch Working Party on Trophoblastic
Disease, founded in 1971, has a registration and advisory
function. The Dutch classiﬁcation system for tropho-
blastic tumours scores for previous failure to chemother-
apy, localisation of metastases, antecedent pregnancy
and the interval between end of pregnancy and beginning
of treatment (Table 1). Patients treated with EMACP or
EMA/CO from 1982 to 2009 were identiﬁed from the
databases of the DCRHM and the DutchWorking Party
on Trophoblastic Disease. Patients treated with other
multi-agent chemotherapy administered before the start
of EMACP or EMA/CO, patients diagnosed with PSTT
and patients with a non-gestational tumour were
excluded. In total, 83 patients treated with EMACP
and 103 patients treated with EMA/CO were included
in this study. Medical records of all patients were
reviewed for age at diagnosis, antecedent pregnancy,
date of evacuation, histology of the tumour, localisation
of metastases, indication for treatment with ﬁrst multi-
agent chemotherapy and duration of follow-up.
2.2. Treatment
The EMACP and EMA/CO chemotherapy regimens
are shown in Table 2. In the EMACP regimen, the inter-
val between courses is 21 days. After normalisation of
the serum hCG concentration generally two courses of
chemotherapy were given to prevent disease relapse. In
the EMA/CO regimen, interval between courses is
15 days. After normalisation of the serum hCG the
national guideline advises three courses of consolidation
chemotherapy.12 Drug resistance was deﬁned as steady
Table 1
Risk classiﬁcation of GTN by the Dutch Working Party on Tropho-
blastic Disease.
Low-risk GTN Demands all of the following conditions:
1. Antecedent pregnancy: hydatidiform mole
or abortiona
2. No metastases or metastases in vagina or
lung
3. No previous chemotherapy
4. Interval between evacuation and start of
chemotherapy less than 12 months
High-risk GTN Demands one or more of the following
conditions:
1. Failure of previous (mono-) chemotherapy
2. Metastases in more than one site (outside
the uterus)
3. Metastases in one or more of the following
organs: liver, spleen, kidney, gastrointesti-
nal tract, bones or brain
4. Antecedent pregnancy: term
5. Interval between end of antecedent preg-
nancy and start of chemotherapy more
than 12 months
a There is no consensus on classiﬁcation of non-molar abortion as
low- or high-risk disease.
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resistance occurred most patients were treated with sur-
gery, salvage chemotherapy treatment or both.
2.3. Outcome measures
Outcome measures were the percentage of patients
that achieved a complete remission, deﬁned as a normal
hCG value after completion of treatment (without con-
solidation courses), and the median number of chemo-
therapy courses required to achieve complete
remission. Also, the percentage of patients with recur-
rent disease and the disease speciﬁc survival was regis-
tered after 24 months of follow-up from the start of
treatment. The cut-oﬀ point of 24 months was chosen
because the national guidelines recommend 2 years of
follow-up after treatment for high-risk GTN, since the
chance of relapsed disease is the highest within the ﬁrst
year of remission, and 85% of all episodes of disease
relapse occur within 18 months of remission.12,13
Short-term toxicities were registered according to the
Common Terminology Criteria for Adverse Events
v3.0 (CTCAE). Also long-term toxicities, including sec-
ondary malignancies were registered. Data on toxicity
were obtained from the medical records and if used,
from the Systemic Therapy Checklist designed by the
EORTC.14
2.4. Statistical analysis
Statistical analysis was performed using SPSS soft-
ware (version 18). Patient characteristics, remission rates
and toxicity were compared using Chi-square test. Mean
age was compared using Student t-test. The mediannumber of chemotherapy courses to hCG normalisation
was compared using the non-parametric independent-
samples median test. p values of less than 0.05 were con-
sidered statistically signiﬁcant.3. Results
Patient characteristics are shown in Table 3. In total,
83 patients were treated with EMACP, of which 16
patients received a modiﬁed schedule without MTX
(ECAP). Patients treated with EMA/CO were signiﬁ-
cantly older (mean 32 years) than patients treated with
EMACP (mean 29 years, p = 0.008). The antecedent
pregnancies from patients treated with EMACP were
not signiﬁcantly diﬀerent from patients treated with
EMA/CO. The indications for treatment were signiﬁ-
cantly diﬀerent between patients treated with EMACP
and those treated with EMA/CO (p = 0.023). Patients
treated with EMACP more often were treated for sin-
gle-agent resistant disease (63.9%) compared to EMA/
CO patients (43.7%). More patients treated with
EMA/CO had primary high-risk disease (42.7%) com-
pared to patients treated with EMACP (27.7%). Seven
patients (8.4%) were treated with EMACP and 14
patients (13.6%) with EMA/CO because of disease
relapse after single-agent chemotherapy. Median fol-
low-up from the start of treatment was 33.3 months
(range 3.9–246.9 months).3.1. Acute toxicity
Table 4 shows toxicity proﬁles for EMACP and
EMA/CO. Three patients died from sepsis related to
treatment, of which one patient was treated with
EMACP and two were treated with EMA/CO. Patients
treated with EMACP more often developed fever (22.9%
versus 11.7%, p = 0.041), renal toxicity (15.7% versus
4.9%, p = 0.013), nausea (48.2% versus 28.2%,
p = 0.005) and diarrhoea (13.3% versus 3.9% p = 0.02)
compared to patients treated with EMA/CO. Patients
treated with EMA/CO more often had anaemia
(28.8% versus 7.2%, p < 0.001), although the incidence
of leucopenia and thrombocytopenia was not signiﬁ-
cantly diﬀerent. In addition, they more often developed
neuropathy (26.2% versus 6.0%, p < 0.001) and hepato-
toxicity (16.5% versus 6.0%, p = 0.028).
The number of patients in whom the dose of chemo-
therapy had to be reduced was not signiﬁcantly diﬀerent
between EMA/CO and EMACP (21.4% versus 27.7%),
but in more patients treated with EMACP one or more
courses had to be delayed due to toxicity or myelosup-
pression (36.1% versus 20.4%, p = 0.017). In patients
treated with EMACP, a total of 330 courses were
administered. Patients treated with EMA/CO received
a total of 688 courses. Dose reduction occurred in 39
(11.8%) of EMACP courses and in 60 (8.7%) of EMA/
Table 2
(a) EMACP regimen and EMA/CO regimen for high-risk gestational trophoblastic neoplasia and (b) the accumulated dosage per week. Interval
between courses is 21 and 15 days, respectively.
(a) EMACP regimen EMA/CO regimen
Day Chemotherapy Dose (i.v.) Day Chemotherapy Dose (i.v.)
1 Etoposide 100 mg/m2 1 Etoposide 100 mg/m2
Methotrexate 300 mg/m2 Methotrexate 300 mg/m2
Cyclophosphamide 600 mg/m2 Actinomycin D 0.5 mg
2 Etoposide 100 mg/m2 2 Etoposide 100 mg/m2
Actinomycin D 0.6 mg/m2 Actinomycin D 0.5 mg
3 Etoposide 100 mg/m2 8 Vincristine 1 mg/m2
4 Etoposide 100 mg/m2 Cyclophosphamide 600 mg/m2
Cisplatin 60 mg/m2
5 Etoposide 100 mg/m2
(b) EMACP regimen EMA/CO regimen
Etoposide 166.7 mg/m2 Etoposide 100 mg/m2
Methotrexate 100 mg/m2 Methotrexate 150 mg/m2
Cyclophosphamide 200 mg/m2 Cyclophosphamide 300 mg/m2
Actinomycin D 0.2 mg/m2 Actinomycin D 0.5 mg
Cisplatin 20 mg/m2 Vincristine 0.5 mg/m2
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ropathy) (p = 0.119). Delay of chemotherapy was
required in 45 courses (13.6%) of EMACP, compared
to 33 (4.8%) of EMA/CO courses that were given with
delay (p < 0.001).
3.2. Late toxicity
In total, seven patients developed secondary malig-
nancies, of which two patients died. After EMA/CO,
four patients developed a secondary malignancy
(3.9%): two Acute Myeloid Leukaemia (AML), one
patient developed Chronic Myeloid Leukaemia (CML)
and one patient died from multiple myeloma 16 years
after treatment with EMA/CO. Three patients devel-
oped a secondary tumour after EMACP (3.6%). One
developed myelodysplastic syndrome (refractory anae-
mia with excess blasts (RAEB)), and two patients devel-
oped AML, of which one patient died, 40 months after
start of treatment. None of the patients had a cumula-
tive etoposide dose exceeding 2 g/m2.
3.3. Response to treatment
Table 5 shows remission rates achieved with EMACP
and EMA/CO for single-agent resistant disease, primary
high-risk disease and relapsed disease after initial remis-
sion on single-agent chemotherapy. In total, 76 out of 83
patients achieved disease remission with EMACP
(91.6%), compared to 88 out of 103 patients treated with
EMA/CO (85.4%), which was not signiﬁcantly diﬀerent.
Remission was achieved in 52 of 53 (98.1%) patients that
were treated with EMACP after failure of initial single-
agent chemotherapy, compared to 44 of 45 (97.8%) in
patients treated with EMA/CO, which was not signiﬁ-
cantly diﬀerent. Median number of EMACP courses
to achieve normal serum hCG concentrations in thesepatients was 1.5 (range 1–5) compared to a median of
three (range 1–6) courses of EMA/CO (p = 0.001). In
78.3% (18 out of 23) and 72.7% (32 out of 44) of patients
that were primarily classiﬁed as high-risk GTN, disease
remission was achieved with EMACP and EMA/CO,
respectively (not signiﬁcant). They received a median
of three EMACP courses (range 2–7) and ﬁve EMA/
CO courses (range 3–13) to achieve normal serum
hCG concentrations (p < 0.001). In 85.7% (six out of
seven) of patients treated for disease relapse after sin-
gle-agent chemotherapy disease remission was achieved
with a median of one course of EMACP. Complete
remission was also achieved in 85.7% (12 out of 14) of
these patients treated with EMA/CO, but with a median
of two (range 1–4) courses (not signiﬁcantly diﬀerent).
The median duration of treatment to achieve disease
remission for single-agent resistant disease, primary high
risk disease and relapsed disease, respectively, is 6, 10
and 4 weeks with EMA/CO, compared to 4.5, 9 and
3 weeks with EMACP.
Of the 17 patients treated with EMACP for post-term
GTN, 14 went into remission (82.4%) with a median of
three courses. Of the 38 patients treated with EMA/CO
that had an antecedent term pregnancy, 28 patients
(73.7%) went in remission (data not shown). These
patients received a median of ﬁve courses of EMA/CO
to achieve normalisation of the hCG concentration
(range 1–13). During follow-up, 10 patients out of 76
patients that initially went into remission with EMACP
subsequently developed recurrent disease (13.2%), com-
pared to four out of 88 patients that achieved disease
remission with EMA/CO (4.5%, p = 0.049).
Seven patients did not achieve disease remission with
EMACP. Two patients had an additional hysterectomy
and one patient was switched to EMA/CO due to severe
toxicity of EMACP. One patient developed a severe sep-
sis and died after the ﬁrst EMACP course. Another
Table 3
Patient characteristics.
EMACP (n = 83) EMA/CO (n = 103) p
Age at diagnosis (years) 0.008
Mean (SD) 29 (6) 32 (6.2)
Antecedent pregnancy NS
Hydatidiform mole 62 (74.7%) 59 (57.3%)
Term pregnancy 17 (20.5%) 38 (36.9%)
Non-molar abortion 2 (2.4%) 4 (3.9%)
Uncertain 2 (2.4%) 2 (1.9%)
Indication for treatment 0.023
Single-agent resistant disease 53 (63.9%) 45 (43.7%)
Primary high-risk disease 23 (27.7%) 44 (42.7%)
Disease relapse after MTX 7 (8.4%) 14 (13.6%)
SD, standard deviation; MTX, methotrexate.
Table 4
Toxicity proﬁle for EMACP (n = 83) and EMA/CO (n = 103).
Toxicity EMACP EMA/CO p
Number of patients (%) Number of patients (%)
Myelosuppression
Anaemia 6 (7.2%) 29 (28.2%) <0.001
Leucopoenia 50 (60.2%) 50 (48.5%) NS
Thrombocytopenia 6 (7.2%) 4 (3.9%) NS
Fever 19 (22.9%) 12 (11.7%) 0.041
Neuropathy 5 (6.0%) 27 (26.2%) <0.001
Renal toxicity 13 (15.7%) 5 (4.9%) 0.013
Hepatotoxicity 5 (6.0%) 17 (16.5%) 0.028
Gastro-intestinal
Mucositis 16 (19.3%) 10 (9.7%) NS
Nausea 40 (48.2%) 29 (28.2%) 0.005
Diarrhoea 11 (13.3%) 4 (3.9%) 0.02
Dose reduction 23 (27.7%) 22 (21.4%) NS
Delay in courses 30 (36.1%) 21 (20.4%) 0.017
Secondary malignancy 3 (3.6%) 4 (3.9%) NS
Death 1 (1.2%) 2 (1.9%) NS
NS, not signiﬁcant.
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sumed drug resistance, however, this was due to the use
of another hCG assay. In one patient the hCG concen-
tration was decreasing but upfront she agreed on per-
forming a hysterectomy if after four courses of
EMACP the hCG was not normalised. One patient ini-
tially treated with EMACP, died from metastatic disease
23 months after diagnosis. She presented with a chorio-
carcinoma after a term pregnancy with metastases to
liver and lungs, and was treated with extensive chemo-
therapy and radiotherapy but subsequently developed
bone and brain metastases.
Fifteen patients did not achieve disease remission
with EMA/CO. Seven patients were switched to a plat-
inum-containing chemotherapy regimen. Five patients
were treated with a platinum-containing chemotherapy
regimen and hysterectomy. Two patients died during
EMA/CO due to sepsis, and one patient was cured with
hysterectomy only.Five patients died from GTN or the given treatment
within the 24 months of follow-up. Disease speciﬁc sur-
vival of EMACP patients was 96.4% (80 out of 83) and
98.1% (101 out of 103) of patients initially treated with
EMA/CO.
4. Discussion
The present study showed that 91.6% of patients trea-
ted with EMACP achieved disease remission compared
to 85.4% of patients treated with EMA/CO. Patients
treated for primary high-risk disease, single-agent resis-
tant disease and relapsed disease all required less courses
of EMACP to achieve normalisation of serum hCG
compared to patients treated with EMA/CO. Patients
treated with EMACP more often developed fever, renal
toxicity and gastro-intestinal toxicity, and signiﬁcantly
more courses had to be delayed compared to EMA/
CO. However, patients treated with EMA/CO more
Table 5
Remission rates in patients treated with EMACP and EMA/CO for single-agent resistant disease, primary high-risk disease and relapsed disease
after initial remission on single-agent chemotherapy.
Treatment indication EMACP EMA/CO
n CRR (%) Number of courses to disease
remission (median)
n CRR (%) Number of courses to disease
remission (median)
Single-agent resistant disease 53 52 (98.1%) 1.5 (4.5 weeks) 45 44 (97.8%) 3 (6 weeks)
Primary high-risk disease 23 18 (78.3%) 3 (9 weeks) 44 32 (72.7%) 5 (10 weeks)
Disease relapse after MTX 7 6 (85.7%) 1 (3 weeks) 14 12 (85.7%) 2 (4 weeks)
Total 83 76 (91.6%) 103 88 (85.4%)
CRR, complete remission rates.
C. Lybol et al. / European Journal of Cancer 49 (2013) 860–867 865often had anaemia, neuropathy and hepatotoxicity. The
number of patients that died from sepsis during treat-
ment and of patients that developed secondary tumours
was comparable in EMA/CO en EMACP.
In previous studies evaluating EMA/CO combination
chemotherapy, a remission rate of 69–86% was
obtained.8–10,15–18 The disease speciﬁc survival rate var-
ies from 85% to 90.9%.8,9,16,17 The remission rate and
disease speciﬁc survival of all EMA/CO patients in our
study were 85.4% and 98.1%, respectively. In the present
study more patients treated with EMA/CO had primary
high-risk disease compared to patients treated with
EMACP. Remission rates were higher in patients who
received prior single-agent chemotherapy compared to
patients that received EMA/CO as ﬁrst treatment for
primary high-risk disease (97.8% versus 72.7% respec-
tively). For comparison, Escobar et al. found that the
complete response to EMA/CO was higher in patients
who received EMA/CO as primary treatment (76%)
than in patients who were treated secondarily with
EMA/CO (65%).18 In contrast, Bower et al. reported
that the complete remission rate after EMA/CO was
not diﬀerent if women received prior chemotherapy
(78% and 79% for ﬁrst and second line treatment).8 Lu
et al. also found the same remission rates in patients
receiving EMA/CO as ﬁrst-line treatment and as sec-
ondary treatment (77.8%).16 The diﬀerences found in
our study might result from a diﬀerence in prior chemo-
therapy. Patients that received prior chemotherapy in
the studies by Bower et al. and Lu et al. had received
either single-agent MTX or combination chemotherapy,
whereas all patients in our study only received previous
single-agent MTX or actinomycin D.
Although less courses of EMACP than EMA/CO
were needed to achieve normal serum hCG, EMACP
is a 3-weekly schedule whereas EMA/CO is a 2-weekly
schedule. Still, the duration of chemotherapeutic treat-
ment, although minimal, is shorter with EMACP. How-
ever, each course of EMA/CO requires only 1 day of
hospital admittance every 2 weeks for the administra-
tion of the EMA part of the course, since the CO part
on day 8 can be given in the outpatient clinic. In con-
trast, administration of the EMACP schedule requires5 days of hospital admittance (days 1–5) every 3 weeks,
which is a higher burden for the patient and is less cost-
eﬀective. In this respect, EMA/CO therefore seems pref-
erable over EMACP. If the diﬀerence in number of con-
solidation courses would be included, patients treated
with EMA/CP, who received two consolidation courses,
would have received 3.5, 5 and 3 courses for single-agent
resistant disease, primary high risk disease and relapsed
disease, respectively, compared to 6, 8 and 5 courses of
EMA/CO, since for the EMA/CO regimen three consol-
idation courses are advised. However, signiﬁcantly more
patients developed recurrent disease after EMACP
(13.2%) than after EMA/CO (4.5%), which may warrant
the need for three courses of consolidation therapy of
EMACP to obtain sustained remission.
The relatively high risk of developing secondary
malignancy found is most likely brought about by eto-
poside.19 Pedersen-Bjergaard et al. reported on ﬁve
patients with leukaemic complications among 82
patients who received a cumulative dose of more than
2 g/m2 etoposide, whereas no leukaemias were observed
among 130 patients who had received up to 2 g/m2.20,21
Each course of EMA/CO contains 200 mg/m2 of etopo-
side compared to 500 mg/m2 in the EMACP schedule.
Therefore the cumulative dose of 2 g/m2 is reached after
four courses of EMACP and only after 10 courses of
EMA/CO. All three patients that developed secondary
tumours after EMACP received four courses of
EMACP. Of the four patients who developed secondary
malignancies after EMA/CO, in none of the patients this
dose was reached. However, more recent reports suggest
that the risk estimate after moderate cumulative doses
(1.5–3 g/m2) was virtually identical to the risk estimate
for patients who received etoposide at a dose of less than
2.0 g/m2.22 Etoposide is a cell-cycle speciﬁc agent, and
large diﬀerences have been reported for diﬀerent sched-
ules. A schedule of ﬁve consecutive daily infusions is
much more active than 24-h infusion of the same total
dose.23 Similarly, increased leukaemogenicity was sug-
gested for these intermittent administration schedules.
Cisplatin has previously been identiﬁed as an active
agent for high-risk GTN.24 Currently, it is used in
patients who have failed initial combination chemotherapy
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etoposide and cisplatin for cyclophosphamide and vin-
cristine in the EMA/CO protocol. EP and EMA are
alternated at weekly intervals.24 In contrast to EMACP,
EMA/EP does not contain cyclophosphamide. In addi-
tion, EMA/EP contains a cumulative dose of 250 mg/
m2 etoposide in each course, compared to 500 mg/m2
in the EMACP schedule. However, EMA/EP contains
75 mg/m2 cisplatin in each course compared to 60 mg/
m2 cisplatin in the EMACP schedule. Previously, New-
lands et al. reported signiﬁcant toxicity of EMA/EP che-
motherapy in patients who have relapsed after or who
have become refractory to EMA/CO, with patients suf-
fering from neutropenia (68%), thrombocytopenia
(40%), anaemia (21%) and renal toxicity (41%). Myelo-
suppression caused delays in chemotherapy in 88% of
EMA/EP patients and 38% of patients required dose
reductions.25 Mao et al. reported myelosuppression
and gastro-intestinal problems as the main adverse
eﬀects in 18 patients treated with 74 cycles of EMA/
EP. Because of myelosuppression and hepatotoxicity,
32 courses (43.2%) were delayed.26 This is a much higher
toxicity than the observed toxicity of EMACP in our
study. Adding cisplatin after previous multi-agent che-
motherapy leads to an impaired bone marrow reserve.
It might therefore be advantageous to start chemother-
apy with cisplatin earlier in the course of treatment.
In conclusion, EMACP combination chemotherapy is
an eﬀective treatment for high-risk GTN. The remission
rate of EMACP was comparable to EMA/CO, and
although less courses of EMACP were required to
achieve disease remission, the diﬀerence in duration of
chemotherapeutic treatment is only slightly shorter with
EMACP. Short term toxicity was alternating diﬀerent
between EMACP and EMA/CO, but overall not signiﬁ-
cantly more common in either of them, whereas long-
term toxicity was not diﬀerent between both regimens.
Cisplatin-based chemotherapy in the form of EMACP
in this study was not proven more eﬀective than
EMA/CO. From the results of this study no arguments
could be found to change the current standard with
EMACO.Conﬂict of interest statement
None declared.
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